Hjem › Steatotisk leversygdom
Steatotisk leversygdom kliniske forsøg rekrutterer i USA
65 studier for Steatotisk leversygdom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- San Antonio, TX17 studier
- New York City, NY16 studier
- Miami, FL16 studier
- San Diego, CA14 studier
- Austin, TX13 studier
- Houston, TX13 studier
- Richmond, VA12 studier
- Tucson, AZ10 studier
- Chandler, AZ10 studier
- Orlando, FL9 studier
- Hialeah, FL9 studier
- St. Louis, MO9 studier
- Dallas, TX9 studier
- Durham, NC8 studier
- Dayton, OH8 studier
- Little Rock, AR8 studier
- Los Angeles, CA8 studier
- New Orleans, LA8 studier
- Pasadena, CA8 studier
- Ocala, FL8 studier
- Rochester, MN8 studier
- Akron, OH7 studier
- Seattle, WA7 studier
- Washington, DC7 studier
- Parma, OH7 studier
- Lancaster, CA7 studier
- Brownsville, TX7 studier
- Topeka, KS7 studier
- Las Vegas, NV7 studier
- Round Rock, TX7 studier
- Chicago, IL6 studier
- Sugar Land, TX6 studier
- Cape Coral, FL6 studier
- Sarasota, FL6 studier
- Sandy Springs, GA6 studier
- Peoria, AZ6 studier
- Indianapolis, IN6 studier
- Fort Worth, TX6 studier
- Fayetteville, NC6 studier
- Arlington, TX6 studier
Efter delstat
- Alabama4 studier
- Arizona14 studier
- Arkansas8 studier
- Californien22 studier
- Colorado6 studier
- Connecticut5 studier
- Florida20 studier
- Georgia8 studier
- Illinois6 studier
- Indiana9 studier
- Iowa4 studier
- Kansas7 studier
- Kentucky4 studier
- Louisiana11 studier
- Maryland8 studier
- Massachusetts9 studier
- Michigan8 studier
- Minnesota9 studier
- Mississippi5 studier
- Missouri14 studier
- Nevada7 studier
- New Jersey6 studier
- New Mexico3 studier
- New York17 studier
- North Carolina13 studier
- Ohio15 studier
- Pennsylvania5 studier
- Rhode Island3 studier
- South Carolina5 studier
- Tennessee7 studier
- Texas20 studier
- Utah5 studier
- Virginia14 studier
- Washington7 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 30. sep. 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 30. sep. 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 28. sep. 2026 · NCT05832229Early Tracking of Childhood Health Determinants (ETCHED) Study
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
1 Day – 99 Years · Alle køn · Opdateret 28. sep. 2026 · NCT03481829A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07165028Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RekruttererFase 2
Alder 5 til 16 · Alle køn · Opdateret 22. sep. 2026 · NCT06133101A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 17. sep. 2026 · NCT07221188Fully Automated High-Throughput Quantitative MRI of the Liver
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 7 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT05294471A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 9. sep. 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 3. sep. 2026 · NCT06419374Human Models of Selective Insulin Resistance: Alpelisib, Part I
RekruttererFase 1Frivillige med god helbredstilstand velkomne
Alder 18 til 70 · Alle køn · Opdateret 24. aug. 2026 · NCT06354088Quantifying Hepatic Mitochondrial Fluxes in Humans
RekruttererFase 4
Alder 18 til 80 · Alle køn · Opdateret 17. aug. 2026 · NCT05305287InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alle aldre · Alle køn · Opdateret 17. aug. 2026 · NCT05463796Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
RekruttererFrivillige med god helbredstilstand velkomne
Alder 25 til 55 · Alle køn · Opdateret 12. aug. 2026 · NCT06993454Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RekruttererFase 2Frivillige med god helbredstilstand velkomne
Alder 18 til 100 · Alle køn · Opdateret 10. aug. 2026 · NCT03884075Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 til 70 · Alle køn · Opdateret 6. aug. 2026 · NCT06335771Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 til 70 · Alle køn · Opdateret 6. aug. 2026 · NCT06571474Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Rekrutterer
Alder 30 til 70 · Alle køn · Opdateret 6. aug. 2026 · NCT07646197A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
RekruttererFase 2
Alder 18 til 70 · Alle køn · Opdateret 3. aug. 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
RekruttererFase 4Frivillige med god helbredstilstand velkomne
Alder 18 til 75 · Alle køn · Opdateret 31. jul. 2026 · NCT06374875Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RekruttererObservationsstudie
Alder 12 til 18 · Alle køn · Opdateret 30. jul. 2026 · NCT04634643Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.